Europe and Japan Allergy Immunotherapy Market to Surpass US$ 1,228.37 Mn by 2030

Europe and Japan Allergy Immunotherapy Market, by Treatment (Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT)), by Allergy Type (Allergy Rhinitis, Allergy Asthma, Pollen Allergies {Cedar, Birch, Oak and Others}, Pet Allergy {Cats, Dogs and Other Pets}, Birds Allergy and Others) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (Europe and Japan), is estimated to be valued at US$ 2,293.56 Million in 2022 and is expected to exhibit a CAGR of 8.1% during the forecast period (2022-2030).

Key players are engaged in conducting research and development activities for development of allergy immunotherapy. This is expected to drive growth of the Europe and Japan allergy immunotherapy market, over the forecast period. For instance, in 2021, Regeneron Pharmaceuticals, Inc., a biotechnology company, announced detailed results from a Phase II proof-of-concept trial evaluating the investigational antibody cocktail REGN1908-1909 in cat-allergic patients with mild asthma.

Market players are involved in entering into agreement with other companies, in order to increase funding for research and development activities as well as development of product pipeline. This is expected to drive growth of the Europe and Japan allergy immunotherapy market over the forecast period. For instance, in 2019, Aimmune Therapeutics, Inc., a Nestlé Health Science Company, entered into a loan agreement of approximately US$ 170 million, with an affiliate of KKR, a leading global investment firm. This agreement helped Aimmune Therapeutics, Inc. to fully fund the commercialization of the AR101 (PALFORZIA), an investigational biologic oral immunotherapy for the treatment of peanut allergy. Moreover, this agreement also helped to continue the Phase II clinical trials of the AR201 for egg allergy, which was initiated in the year 2019.

Europe and Japan Allergy Immunotherapy Market- Impact of Coronavirus (COVID – 19) Pandemic

The coronavirus disease (COVID-19) pandemic is expected to limit the growth of the Europe and Japan allergy immunotherapy market over the forecast period. COVID-19 is the recent pandemic outbreak, which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020. According to the World Health Organization (WHO) Weekly epidemiological update on COVID-19, the number of new cases are decreasing after May 22, 2022. Therefore, as of May 22, 2022, the total number of cases reported in Europe were 1,119,084 while in Japan, the total number of cases reported till May 25, 2022 were 8,718,807

Increasing COVID-19 pandemic decreased the use of allergic immunotherapy among patients. This is expected to limit growth of the Europe and Japan allergic immunotherapy market, over the forecast period. According to an article published in the Allergy journal: 2021, in the year 2020, the following bar graph shows the percentage of allergy immunotherapy (AIT) treatments that are carried out (out of 100%) for the prevention of allergic symptoms in patients, during the COVID-19 pandemic. The following graph shows that the percentage of AIT therapies has decreased during COVID-19, but not completely stopped.

Browse 45 Market Data Tables and 39 Figures spread through 508 Pages and in-depth TOC on Europe and Japan Allergy Immunotherapy Market, by Treatment (Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT)), by Allergy Type (Allergy Rhinitis, Allergy Asthma, Pollen Allergies {Cedar, Birch, Oak and Others}, Pet Allergy {Cats, Dogs and Other Pets}, Birds Allergy and Others) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and by Region (Europe and Japan).

To know the latest trends and insights prevalent in the allergy immunotherapy market, click the link below:

https://www.coherentmarketinsights.com/market-insight/europe-and-japan-allergy-immunotherapy-market-5037

Market players are involved in inorganic activities such as collaborations, in order to expand their product portfolio. This is expected to drive the growth of the Europe and Japan allergy immunotherapy market. For instance, in 2020, Stallergenes Greer, a Biopharmaceutical Company, and its partner, Alyatec, a contract research organization based in Strasbourg University Hospital (France), entered into a collaboration, in order to advance precision medicine in allergen immunotherapy (AIT).

Key Takeaways of the Europe and Japan Allergy Immunotherapy Market:

• Europe and Japan allergy immunotherapy market is expected to exhibit a CAGR of 8.1% over the forecast period (2022-2030), owing to growth in potential markets, in Europe.
• Market players are initiating research and development activities for the development of allergy immunotherapy drugs. This is expected to drive growth of the Europe and Japan allergy immunotherapy market, over the forecast period. For instance, in October 2020, Allergy Therapeutics Plc initiated the screening of the first patient in its clinical trial study which was carried out to evaluate the efficacy and safety of Grass MATA MPL in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure.
• Major players operating in the Europe and Japan allergy immunotherapy market include Novartis International AG, Merck & Co., Inc., Aimmune Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., HAL Allergy B.V., Stallergenes Greer, ALK-Abelló A/S, Allergy Therapeutics Plc, Torii Pharmaceutical Co., Ltd., and DESENTUM OY.